Olumiant ® (baricitinib) tabletter

För fullständig produktresumé för Olumiant se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Olumiant®▼ (baricitinib): Dosering för måttlig till svår reumatoid artrit

Rekommenderad dos av Olumiant är 4 mg en gång dagligen.

Dose Modifications

The recommended dose of BARI is 4 mg once daily.

A dose of 2 mg once daily is appropriate for

  • patients such as those aged ≥ 75 years and may be appropriate for patients with a history of chronic or recurrent infections.

  • patients who have achieved sustained control of disease activity with 4 mg once daily and are eligible for dose tapering.1

  • patients with creatinine clearance (eGFR) between 30 and 60 mL/min.1

  • patients taking OAT3 inhibitors with a strong inhibition potential, such as probenecid, is 2 mg once daily.1

Use of BARI is not recommended in patients with

  • estimated glomerular filtration rate of < 30 mL/min/1.73 m2.

  • severe hepatic impairment

  • absolute lymphocyte count <500 cells/mm3

  • absolute neutrophil count <1000 cells/mm3, or

  • hemoglobin level <8 g/dL.1

Use of BARI is not recommended in pediatric patients.1 

Route of administration

Baricitinib is an oral drug to be given daily.1

References

1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M04 30

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss